28 results on '"Borghesio E"'
Search Results
2. Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study
3. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
4. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
5. Autoimmunty in patients with chronic hepatitis type D and C
6. P.03.8 PEG-IFN FOR CHRONIC HEPATITIS C IN CLINICAL PRACTICE: THE PROSPECTIVE PHASE OF THE AIFA STUDY
7. OC-35 PEG-IFN for chronic hepatitis C in clinical practice: the prospective phase of the AIFA study
8. P.1.146: CD86 GENETIC VARIANTS ARE ASSOCIATED WITH COLORECTAL CANCER (CRC) AND ULCERATIVE COLITIS, BUT NOT ADENOMA, RISK: A CLUE TO A DIFFERENT PATHOGENETIC MECHANISM OF CRC?
9. P.1.31: VARIANTS OF THE OBESITY-ASSOCIATED FTO GENE AND COLORECTAL CANCER RISK IN ITALY
10. OC.09.7: PEG-IFN FOR HEPATITIS C IN CLINICAL PRACTICE: RESULTS OF THE RETROSPECTIVE PHASE OF THE AIFA STUDY
11. OC.09.4: RELATIONSHIP OF GENETIC VARIATIONS OF THE GENE CODING FOR THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1 (HENT1) WITH PROTEIN EXPRESSION AND RESPONSE TO TREATMENT IN CHRONIC HEPATITIS C
12. T-38 PEG-IFN for hepatitis C in clinical practice: Results of the retrospective phase of the AIFA study
13. PEG-IFN for hepatitis C in clinical practice
14. PA.72 CTLA4 AND MMP1 POLYMORPHISMS DISTRIBUTION IN PRIMARY BILIARY CIRRHOSIS RAPIDLY EVOLVING TO LIVER FAILURE
15. CTLA4 AND MMP1 POLYMORPHISMS DISTRIBUTION IN PRIMARY BILIARY CIRRHOSIS RAPIDLY EVOLVING TO LIVER FAILURE.
16. RELATIONSHIP BETWEEN C/T_13910 POLYMORPHISM INVOLVED IN THE ADULT LACTASE PERSISTENCE AND RISK OF COLORECTAL CANCER IN THE ITALIAN POPULATION.
17. MTHFR C677T AND A1298C POLYMORPHISMS AND SPORADIC COLORECTAL CARCINOMA RISK IN A COHORT OF ITALIAN PATIENTS.
18. 178 MEGX TEST AND MAYO CLINIC PROGNOSTIC SCORE IN PRIMARY BILIARY CIRRHOSIS (PBC).
19. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
20. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
21. 1155 PEG-IFN FOR CHRONIC HEPATITIS C IN CLINICAL PRACTICE: THE PROSPECTIVE PHASE OF THE AIFA STUDY
22. LCT-13910C>T polymorphism-associated lactose malabsorption and risk for colorectal cancer in Italy.
23. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.
24. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
25. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation.
26. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
27. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?
28. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.